KDM3A and Miyoshi myopathy: Furthermore, KLF2 binds with lysine demethylase 3A (KDM3A) and interferon regulatory factor 4 (IRF4) to increase MM cell adhesion to bone marrow stromal cells and accelerate MM cell homing to the bone marrow, which suggests KLF2 as a potential therapeutic target in MM [10].